Announcements Trials
Browse Landscape

Phase

Phase 2 9Phase 3 5Phase 1/2 3Phase NA 1Phase EARLY_PHASE1 1Phase 2/3 1Phase 1 1

Status

Recruiting 3Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 3OTHER 1NETWORK 1

Study Type

Interventional 5

Sponsor

Cancer Type

Gastrointestinal 5

Conditions

Pancreatic Neoplasms 4Metastatic Adenocarcinoma of the Pancreas 1

Interventions

pembrolizumab 130Carboplatin 127Cisplatin 118Paclitaxel 99Gemcitabine 87Specimen Handling 80Magnetic Resonance Spectroscopy 80Docetaxel 70Dexamethasone 62Cyclophosphamide 61Pemetrexed 59Capecitabine 56Bevacizumab 56durvalumab 52Oxaliplatin 52Fluorouracil 50Doxorubicin 49Radiotherapy 48Leucovorin 45Radiation 44Rituximab 43Lenalidomide 42Vincristine 39Etoposide 36Nivolumab 34atezolizumab 33Letrozole 32130-nm albumin-bound paclitaxel 32Irinotecan 31Prednisone 29

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 3 × irinotecan sucrosofate × 90 days × Clear all
NCT06998940 2026-05-22

Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations

SWOG Cancer Research Network

Phase 3 Recruiting
94 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT07409272 2026-05-18

A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer

Astellas Pharma Inc

Phase 3 Recruiting
614 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT06958328 2026-05-04

LAP100

NRG Oncology

Phase 3 Recruiting
356 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT06625320 2026-04-27

RASolute 302

Revolution Medicines, Inc.

Phase 3 Active not recruiting
500 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT04083235 2026-04-20

NAPOLI 3

Ipsen

Phase 3 Completed
770 enrolled 13 charts 1 FDA
Gastrointestinal

Metastatic Adenocarcinoma of the Pancreas

Data powered by HemOnc (CC BY 4.0) Colophon âš¡